Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders. Further, provided herein are non-invasive methods and systems for assessing a subject's risk of having NASH. Moreover, provided herein are non-invasive methods and systems for evaluating whether a treatment of NASH is effective.

The present invention relates to a method for quantification of amino acids using a cell-free protein synthesis system. Specifically, the present invention relates to a method for quantification of amino acids, comprising: (a) preparing a reaction mixture for cell-free protein synthesis without target amino acids; (b) performing cell-free protein synthesis by mixing an assay sample containing target amino acids with the reaction mixture for cell-free protein synthesis; (c) measuring the signal intensity of the synthesized protein; and (d) calculating the concentration of the target amino acids by comparing the measured signal intensity with the standard concentration curve for each amino acid according to the protein signal produced using a standard sample, a method for providing information for diagnosing an amino acid metabolism-related disease using the same, a method for screening a material for prevention or treatment of an amino acid metabolism-related disease, and a method for screening a transaminase substrate. The method for quantification of amino acids according to the present invention can quantify amino acids in a short time at a low cost, and thus can be useful in various industries.

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

Provided is a method of assisting the detection of nonalcoholic steatohepatitis (NASH), which is far less invasive than liver biopsy and is based on simple operations that do not require skilled technical personnel.

The present invention is a method of assisting the detection of NASH, which includes: a) measuring the amount of LDL-TG contained in a test blood sample isolated from a living body; b) measuring the amount of at least one component selected from the group consisting of LDL-C, LDL subfraction-C, IIDL-C, HDL subfraction-C, ApoB, ApoE, total cholesterol, ALT, and AST contained in the test blood sample; and c) determining the possibility of developing and/or having NASH by using the amount of LDL-TG in combination with the amount of the at least one component.

An object of the present invention is to provide a blood analysis method and a blood test kit, which are for performing quantitative analysis of components by precisely obtaining a dilution factor. According to the present invention, provided is a blood analysis method including a step of diluting a collected blood sample with a diluent solution; a step of determining a dilution factor by using a normal value of a normal component which is homeostatically present in blood; and a step of analyzing a concentration of a target component in the blood sample, in which the blood analysis method uses a member selected from the group consisting of a first storing instrument for storing a diluent solution, a separation instrument for separating and recovering blood plasma from the blood sample diluted with the diluent solution, a holding instrument for holding the separation instrument, a second storing instrument for storing the recovered blood plasma, and a sealing instrument for keeping the stored blood plasma within the second storing instrument, in which the diluent solution defines an amount of the normal component which is derived from the diluent solution and/or the members and may be contained in the diluent solution, and in which a volume of the blood sample is 50 μL or less, and a dilution factor of a blood plasma component in the blood sample is 14 times or more.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

The invention relates to the use of an immunologically reactive microbial transglutaminase or its immunologically reactive parts or analogues, which are present in a complex with gliadin or its immunologically reactive parts or analogues, for the diagnosis and/or therapy control of coeliac disease or sprue as well as gluten sensitivity, and a kit for determining the diagnosis and/or therapy control of coeliac disease or sprue as well as of gluten sensitivity, by means of the previously mentioned complex.

Treatment of multiple myeloma with a combination of panobinostat and bortezomib at specified doses adjusted for safety.

Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.

The present disclosure relates generally to methods for using pexidartinib and related Risk Evaluation and Mitigation Strategy (REMS), while reducing the occurrence of hepatotoxic adverse events.